Introduction
cess. 6, 7 The high risk of morbidity and mortality and lack Hurler syndrome is a severe lysosomal storage disorder of HLA-matched siblings are the major limitations to the caused by the deficiency of ␣-l-iduronidase (IDUA), routine use of allogeneic transplantation. which is required for stepwise degradation of the glycosThe possibility of enzyme replacement therapy for aminoglycans heparan sulfate and dermatan sulfate. Lack many MPS diseases was suggested when Fratantoni and of the IDUA enzyme results in a spectrum of clinical finco-workers 8 discovered that 'corrective factors' could be dings including hepatosplenomegaly, skeletal deformitexchanged between cultured fibroblasts from patients ies, coarse facial features, corneal clouding and neurowith different lysosomal storage diseases. It is now logical deterioration. 1 The human IDUA gene has known that these lysosomal enzymes are processed postrecently been cloned and is located on chromosome translationally by addition of mannose-6-phosphate resi4p16.3. [2] [3] [4] More than 50 mutations of the human IDUA dues, allowing them to traffic in and out of cells and to gene have been reported. 5 Different types of mutations be compartmentalized into lysosomes through a highly including nonsense, mis-sense, and point mutations in efficient receptor-mediated mechanism. 9, 10 This suggests introns give rise to a spectrum of clinical phenotypes. that overexpression of IDUA by a small number of cells Hurler syndrome shows the most severe clinical features may provide benefit in trans to other cells and thus have including severe mental retardation, Hurler/Scheie syntherapeutic benefits for these diseases. drome is intermediate in severity and Scheie syndrome Several groups have been evaluating the possibility of is milder and involves no neurological defects. 1 gene therapy of the MPS diseases using different cell Existing conventional therapies for lysosomal distypes and in different animal models. These studies orders are limited to symptomatic treatment and palliinclude: (1) the demonstration of a reversal of phenotypes ative procedures. Allogeneic bone marrow transplanof enzyme-deficient fibroblasts when they were transtation has been attempted for the treatment of many duced with a retroviral vector carrying a relevant gene;
In addition, the relative success of allogeneic BMT in HuID-SN and PA317/MFG-HuID packaging cell clones providing a source of enzyme for clearing storage compared to normal human fibroblasts (data not shown). materials in some organs and alleviating symptoms sugIn addition, immunohistochemical staining of PA317/Lgests that hematopoietic stem cell gene therapy, through
HuID-SN cells with this polyclonal antibody showed a introducing a normal copy of the IDUA cDNA into autostrong staining compared with that of PA317/LN cells logous bone marrow, may provide similar benefits as ( Figure 2 ). allogeneic BMT without the immunological compliTo confirm that the retroviral vectors were not cations. 14, 15 Effective gene therapy requires efficient gene rearranged during packaging, genomic DNA from each transfer, stable integration of the therapeutic gene into packaging cell line was subjected to a set of restriction long-lived hematopoietic stem cells, maintenance of an endonuclease enzyme digestions followed by Southern appropriate level of gene expression and no adverse blot analysis. Genomic DNA from the PA317/L-HuIDimmunological recognition of the gene product. In this SN, the PA317/MFG-HuID and the control PA317/LN study, we showed that human hematopoietic progenitor cells were digested with SstI. When probed with a P 32 -cells transduced by retroviral vectors carrying human labeled human IDUA cDNA fragment, the PA317/L-IDUA cDNA led to the production of high levels of IDUA HuID-SN and the PA317/MFG-HuID clones showed 5.3 in their progeny which can correct enzyme-deficient and 4.2 kb bands, respectively, which indicates complete Hurler fibroblasts.
and non-rearranged proviral DNA structures (Figure 3a) . Genomic DNA of the PA317/LN which serves as a negative control did not show a specific band (Figure 3a) . To obtain the copy numbers of proviral integrants in each
Results
packaging cell line, genomic DNA was digested with either EcoRI or BamHI, each cutting once within the vecCharacterization of packaging cell line tors. Genomic DNA of the PA317/L-HuID-SN and the Two retroviral vectors containing human IDUA cDNA PA317/MFG-HuID showed two and four bands, respectwere constructed and packaged ( Figure 1 ). The first vecively, again with no hybridization bands seen in the tor, L-HuID-SN was constructed by inserting the human PA317/LN (Figure 3a ). This indicates that there are two IDUA cDNA into the widely used Moloney murine leucopies of L-HuID-SN proviral integrants in the PA317/Lkemia virus (MoMLV)-based LXSN vector backbone. The
HuID-SN and four copies of MFG-HuID proviral intesecond vector, MFG-HuID, was constructed in the MFG grants in the PA317/MFG-HuID packaging cell line. Takretroviral vector backbone. ing the copy number of proviral integrants into considerThe endogenous IDUA activity in both human and ation, there was no significant difference in the level of murine fibroblasts was 2.0 ± 0.3 units per milligram of enzyme expression between each vector in these two protein. The PA317/L-HuID-SN packaging clone had an packaging cell lines (Table 1) . elevated IDUA activity of 563 ± 74 units, which is Total RNA was extracted from the packaging cell approximately 280-fold higher than that of PA317 conclones and analyzed by Northern blot using a fragment taining a negative control vector (PA317/LN) ( Table 1) .
of the human IDUA cDNA as a probe (Figure 3b ). The The PA317/MFG-HuID packaging clone showed an PA317/L-HuID-SN cells showed the expected 4.6 kb enzyme activity of 112 ± 83 units which is 550-fold higher RNA, representing the full-length transcript from the than that of the background. Western blot analysis using LTR, and the 3.8 kb RNA, representing the spliced proa polyclonal antibody against recombinant human IDUA showed very high IDUA expression in both PA317/Lduct of the full-length transcript. The PA317/MFG-HuID 
transduced Hurler fibroblasts
To analyze the kinetic properties of the secreted IDUA produced by retroviral vector transduced cells, cell medium of L-HuID-SN transduced Hurler fibroblasts K m (uptake), which is the IDUA concentration at which the enzyme internalization reaches its half maximum was collected and the IDUA enzyme was concentrated as described in Materials and methods. Figure 4 shows the rate, showed a value of 13.3 ± 3.1 (n = 3) unit/ml, corresponding to 0.68 ± 0.16 nM of IDUA ( Figure 4 ). The uptake of IDUA into Hurler fibroblasts as a function of enzyme concentration from one of the three experiments.
concentration of IDUA was calculated on the basis of an estimated specific activity of purified human enzyme of When subjected to Michaelis-Menten kinetic analysis, the fold (n = 3) increase, respectively, in IDUA activity when compared with that of sham-transduced cells from normal donor cord blood (Figure 5a ).
To address the question of whether stroma from a Hurler patient can support retrovirus-mediated IDUA gene transfer, one transduction experiment (experiment No. 3 presented in Table 2 ) was performed by using primary stromal cells derived from a Hurler syndrome patient's bone marrow with CD34
+ cells from a normal cord blood sample. The results of this experiment did not show any significant differences in either the efficiency of gene transfer or the level of enzyme expression.
To analyse further if retroviral vector-mediated gene transfer and a high level of IDUA enzyme expression can be achieved in hematopoietic progenitor cells derived from a Hurler syndrome patient, two transduction experiments were performed by using supernatant from the PA317/L-HuID-SN packaging clone. Both the CD34 + cells and the stromal layer were derived from the bone sham-transduced Hurler bone marrow cells (at a nondetectable level), but even showed a significant increase when compared with that of the sham-transduced, norabout 240 000 U/mg protein and the apparent molecular weight of 82 kDa. 16 The K m is computed from a direct mal hematopoietic cells (2.0 ± 0.3 units). In conclusion, the progeny of transduced hematopoietic progenitor cells non-linear least-square fit of velocity data when a double reciprocal plot was applied using 1/velocity of enzyme from either normal individuals or a Hurler syndrome patient can produce high levels of IDUA in long-term internalization vs 1/concentration of IDUA added (Lineweaver-Burk plot). The uptake of the applied bone marrow culture. Stroma derived from a Hurler syndrome patient's bone marrow can support the enzyme was saturable, as expected of a receptormediated process. Addition of 1 mM of mannose-6-phostransduction as well as stroma from normal donors. phate, a competitive inhibitor of IDUA binding to its receptor, inhibited enzyme uptake by more than 95%, whereas mannose-1-phosphate at the same concentration Correction of Hurler fibroblasts by transduced hematopoietic cells had no effect (data not shown). The K m measured in this assay is about the same value as reported for the IDUA IDUA is known to be post-translationally modified by the addition of mannose-6-phosphate to the enzyme's oligosoverproduced by Chinese hamster ovary cells. 16 This indicated that Hurler patients' fibroblasts transduced by accharide side chain. The glycosylated protein is then delivered to lysosomes where the degradation of glycosa-L-HuID-SN can produce properly modified IDUA which can be taken up by enzyme-deficient cells through minoglycan occurs. Excess IDUA can also be secreted and endocytosed by other cells through mannose-6-phosmannose-6-phosphate mediated receptors.
phate mediated receptors. To evaluate the ability of transduced hematopoietic cells to produce and secrete prop-IDUA gene transfer into primary human CD34 + cells and expression in mature hematopoietic cells erly modified IDUA protein, a co-culture experiment was performed. When equal numbers of transduced hematoDue to the limited availability of Hurler patients' bone marrow cells, most experiments were performed using poietic cells were cultured with Hurler fibroblasts in separate chambers of a trans-well device, the Hurler fibro-CD34 + hematopoietic cells from bone marrow or umbilical cord blood of normal donors, unless stated otherwise.
blasts showed an enzyme activity reaching 0.40 ± 0.03 units (n = 2) compared with the non-detectable level of After CD34
+ hematopoietic cells were transduced with viral supernatant, gene transfer efficiency was assessed IDUA activity in Hurler fibroblasts when cultured with hematopoietic cells transduced by the LN vector. In the by methylcellulose-supported progenitor colony-forming unit (c.f.u.) assay. Results showed that the transduction presence of 1 mM mannose-6-phosphate, the enzyme uptake was completely blocked; however, no inhibition efficiency was in the range of 18-25% for both retroviral vectors (Table 2) .
was observed when the same concentration of mannose-1-phosphate was added instead ( Figure 6 ). These results The enzyme activity in the progeny of the transduced CD34 + cell pool was monitored during a period of 21 demonstrated that the transduced hematopoietic cells can provide functional IDUA enzyme which can correct days. Enzyme activity in transduced cells showed an initial linear increase over the first 10 to 12 days, followed enzyme-deficient cells by a mannose-6-phosphate receptor-mediated mechansim even when the enzyme donor by a plateau after 14 days ( Figure 5 ). Hematopoietic cell pools transduced by the L-HuID-SN and the MFG-HuID cells and enzyme recipient cells were physically separated by a membrane. retroviral vectors showed at least a 50-fold (n = 3) and 40- The over-expression of the enzyme in such a cell can deficiency in hematopoietic cells is not a primary probbenefit its surrounding cells by serving as an enzyme lem, the hematopoietic cells may be used to deliver the donor for enzyme-deficient cells. product of the transduced gene to enzyme-deficient cells.
To maximize the level of enzyme expression in transIn our studies, human CD34
+ cells were first isolated duced cells, we compared two vectors carrying human from either bone marrow or umbilical cord blood, IDUA cDNA: the L-HuID-SN, which is an L-X-SN-based induced to cell cycling with growth factors, and then vector, and the MFG-HuID, which is an MFG-based vectransduced by retroviral vectors. We show that in vitro tor. In the MFG vector backbone, a small 350 bp fragment human CD34
+ hematopoietic progenitor cells from either from immediately upstream of the MoMLV envelope umbilical cord blood or bone marrow can be transduced (env) gene was added downstream of the Psi+ leader with retroviral vectors carrying the normal human ␣-lsequence. This small fragment serves as a splicing iduronidase cDNA, and the progeny cells of the transacceptor to generate mRNA for env translation. It has duced progenitors can express high levels of functional been reported that this vector can give increased enzyme for at least 3 weeks in long-term bone marrow expression of an inserted cDNA, due to an increased cultures. Even more importantly, the IDUA enzyme pro-RNA splicing efficiency. 18 Previous studies from our labduced by transduced hematopoietic cells can be released oratory showed that the level of glucocerebrosidase (GC) into the surrounding cell medium and correct enzymeexpression in a murine bone marrow transplantation deficient cells, using a mannose-6-phosphate mediated model was five-to seven-fold higher when the human receptor mechanism. It has been reported that the pres-GC cDNA was carried by an MFG-based vector comence of less than 1% of normal IDUA in patients will pared with that of a LXSN-based vector when corrected moderate the severe clinical symptoms related to Hurler for the number of proviral integrants. Surprisingly, in syndrome.
1 Therefore, even though the gene transduction this current study, we found that the levels of enzyme of pluripotent hematopoietic stem cells using currently expression by the MFG-HuID vector and the L-HuID-SN available procedures is at a lower efficiency, 15 the high vector in both the packaging cell line clones were very level of enzyme expression by transduced cells reported similar when adjusted for the copy numbers of proviral in this study may be sufficient to generate clinical integrant. However, this may not definitely prove that benefits.
the two vectors are equivalent because the levels of A similar study by Fairbairn et al 17 showed that there expression can vary widely among different clones. In was a 10-fold increase of IDUA expression in either proaddition, when the primary hematopoietic cell pools geny of transduced hematopoietic progenitor cells from were transduced with these two retroviral vectors with a Hurler syndrome patient or in extracellular medium of similar transduction efficiency, no significant differences LTBMC with a transduction efficiency of 25-56%. These were observed for the level of enzyme expression. Also results correspond with our observation of a 10-fold in contrast to our reported results with the human glucoincrease in IDUA expression in the progeny of transcerebrosidase cDNA where an increased enzyme duced CD34
+ cells from a Hurler patient with a similar expression by the MFG-GC vector was associated with transduction efficency of 18-24%. In our studies, using an increase in the fraction of the vector-derived tranunaffected normal CD34
+ cells, the elevation of IDUA scripts which were spliced, we did not see a relative expression reached 50-fold compared with that of norincrease in the fraction of MFG-HuID vector transcripts mal, sham-transduced CD34 + cells. When measured on which were spliced compared with the pattern seen with the bulk population of cells, the elevation in the level of IDUA expression was at 100-110 U/mg of protein lysate, the L-HuID-SN vector. In our MFG-HuID vector, the that the enzyme endocytosis is mannose-6-phosphate receptor-dependent ( Figure 6 ). The presence of 1 mM of free mannose-6-phosphate, which is 27-fold above the known K i of mannose-6-phosphate for uptake of urinary ␣-l-iduronidase into Hurler fibroblasts (K i = 0.037 mM), 8 can efficiently competitively inhibit the IDUA enzyme uptake. The presence of the same concentration of mannose-1-phosphate, an isomer of mannose-6-phosphate which would not be expected to compete for the mannose-6-phosphate molecules, had no effect ( Figure 6 ). In summary, we have shown that human hematopoietic progenitor cells can be transduced with retroviral vectors and the resulting cell progeny express high levels of IDUA enzyme. Excess enzyme expressed by transduced hematopoietic cells can be released into the surrounding medium and endocytosed through mannose-6-phosphate mediated receptor mechanism into enzymedeficient cells. Even though there were no significant differences between the L-HuID-SN and the MFG-HuID retroviral vectors as gene delivery vehicles at the level of enzyme expression, the MFG-HuID vector might be a more suitable vector for clinical gene therapy due to the lack of the neomycin resistance gene which might cause an adverse immunological response. Information obtained in this study will allow us to examine the potential of gene therapy via hematopoietic cells for the treatment of Hurler disease.
Materials and methods

Cell lines
The murine fibroblast amphotropic packaging cell line PA317 19 and the murine fibroblast cell line NIH3T3 were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). GP+E86, a murine fibroblast ecotropic packaging cell line 20 was a generous gift from A Bank (Columbia University, New York, NY, was provided by Dr P Robbins acceptor site of the env fragment is required for its enhanced splicing and translation. Alternatively, intrinsic (University of Pittsburgh). The L-HuID-SN retroviral vector ( Figure 1 ) was constructed by subcloning the human aspects of different cDNA may affect the extent of RNA splicing and thus the relative augmentation of expression IDUA cDNA (a generous gift from Dr Neufeld, UCLA) into the LXSN plasmid as an EcoRI/BamHI fragment from the MFG backbone.
IDUA protein molecules which contain mannose-6-from the Bluescript plasmid. The MFG-HuID vector ( Figure 1 ) was constructed by ligation of an phosphate residues are recognized by specific mannose-6-phosphate cell surface receptors. In our studies, we
EcoRV/BamHI blunt-ended human IDUA cDNA fragment from the Bluescript plasmid into a blunt ended NcoI clearly showed that transduced hematopoietic cells can function as enzyme donors to correct enzyme-deficient site of the MFG plasmid. Both retroviral vector plasmids were mapped by restriction endonuclease digestion. Hurler fibroblasts, through a non-contact mechanism and The L-HuID-SN retroviral vector which carries a neoduced with viral supernatants from these clones were tested by polymerase chain reaction for amphotropic env mycin phosphotransferase II gene was first transfected into GP+E86 cells using DOTAP transfection reagent sequences as described. 23 Packaging clones were then expanded, and retroviral supernatants were collected (Boehringer Mannheim, Indianapolis, IN, USA). The transiently produced viruses, which were collected after 48 h, from D-10 medium conditioned by confluent monolayers for 48 h at 32°C. were used to transduce PA317 packaging cells. The transduced PA317 cells were selected in 0.5 mg/ml G418 active compound (GIBCO-BRL). Individual clones were
Immunohistochemical staining isolated, expanded, and screened for viral titer on Packaging cells were trypsinized, washed twice in PBS, NIH3T3 cells with serial dilution of viral supernatant. A and resuspended in PBS at a final concentration of 1 × 10 6 clone producing high viral titer of L-HuID-SN at 1 × 10 6 cells/ml. One hundred microliters of cell suspension G418-resistant c.f.u. per milliliter was obtained. The were centrifuged at 57 g for 5 min on to 1% BSA coated MFG-HuID retroviral vector, which does not contain the glass slides. Slides were air-dried overnight and then G418 drug resistant marker, was first co-transfected with fixed in cold acetone for 15 min. IDUA was detected with pSV2-neo plasmid at a 10:1 ratio into GP+E86 cells, folrabbit anti-human IDUA immunoglobulin (IgG) followed lowed by G418 selection (0.5 mg/ml) for 10 days. The by horse anti-rabbit IgG conjugated with strepavidin-G418-resistant pool of transfected GP+E86 cells was alkaline phosphatase (GIBCO-BRL). Alkaline phosphaexpanded in D-10 medium and viral supernatant was tase was detected with New Fuchsin substrate (Biogenex, used to transduce PA317 cells, which were then cloned San Ramon, CA, USA) and nuclei were counterstained by limiting dilution. Each transduced PA317 clone was using hematoxylin solution. After mounting with aquescreened for the presence of elevated IDUA enzyme ous mounting medium, stained cells were photographed activity in the culture medium. To select a high titer using an Olympus SC35 camera (Olympus, Melville, NY, PA317/MFG-HuID clone, viral supernatant from each USA) at ×40. clone was first diluted 1:10 with D-10 medium to ensure that the transduction of Hurler fibroblasts was in a linear range by using a low multiplicity of infection (MOI) viral Transduction of human Hurler fibroblasts and harvest of IDUA enzyme produced supernatant. Transduction was performed by overlaying 1 ml of diluted viral supernatant on Hurler fibroblasts
Hurler fibroblasts were first plated at 1 × 10 5 cells per plate and transduced with viral supernatant from (5 × 10 4 per well in a six well dish) in the presence of 16 g/ml polybrene for 1 h, and then diluted to 8 g/ml PA317/L-HuID-SN cells three times within 12 h in the presence of 8 g/ml polybrene. After 48 h, the transby addition of 1 ml of fresh medium. Hurler cells were rinsed in Hanks' balance salt solution (HBSS) after 12 h duced Hurler cells were selected in D-10 medium containing 0.5 mg/ml G418 for 10-12 days. When the cells and 2 ml of fresh medium were applied. Once they reached confluence, cells were harvested, rinsed in phosreached confluence, fresh D-10 medium was added and the cell medium was harvested after 48 h. To stabilize the phate-buffer saline (PBS), and analyzed for IDUA activity. A high titer clone was thus selected according IDUA enzyme, NaH 2 PO 4 was added to the collected culture medium to a final concentration of 10 mm to bring to the presence of the highest enzyme activity in the transduced Hurler fibroblasts. Both selected PA317/Lto pH 6.5. Enzyme was concentrated by centrifugation at 4°C using a Centricon filter (30 kDa molecular weight cut HuID-SN and PA317/MFG-HuID clones were confirmed to be negative for helper virus when NIH3T3 cells transoff; Amicon, Beverly, MA, USA). 39 subsequent cycles were identical, except that the denaturation time was reduced to 1 min. The resulting PCR mol/l hydrocortisone (Sigma), 2 mmol/l l-glutamine, and 100 U/ml of pencillin-streptomycin) containing products were electrophoresed on 1.2% agarose gel. The gene transfer efficiency was assessed by taking the numrecombinant human interleukin 6 (rHIL-6) (R&D Systems, Minneapolis, MN, USA) at 50 U/ml, rHIL-3 ber of PCR-positive colonies over the total number of colonies analyzed. (Immunex, Seattle, WA, USA) at 10 ng/ml and stem cell factor (SCF; R&D Systems) at 50 ng/ml. Cells were transduced on a stromal layer by replacing half the volume of Iduronidase enzyme assay To assay the IDUA enzyme activity inside cells, pelleted medium with filtered (0.45 m) viral supernatant from either the PA317/L-HuID-SN or the PA317/MFG-HuID cells were resuspended in 25-50 l of lysis buffer (10 mm NaH 2 PO 4 /NaHPO 4 , pH 5.8, 0.02% sodium azide, 0.1 mm cells. Transductions were performed six times over a period of 72 h with cytokine concentrations maintained as DTT, 0.1% Triton X-100) and lysed by three cycles of freeze-thawing. Cell extracts were cleared by centrifugstated previously and protamine sulfate (Lymphomed, Deerfield, IL, USA) at a final concentration of 4 g/ml.
ation at 16 000 g for 10 min at 4°C. The protein contents of cell lysates were determined using the Pierce BicinAs a negative control, one set of CD34 + cells in each transduction experiment was sham-transduced using D-10 choninic Acid protein kit (Pierce, Rockford, IL, USA). Ten to 30 g of each cell lysate were incubated with 25 l of medium instead of viral supernatant with all of the other transduction conditions remaining the same. After transsubstrate 4-methylumbelliferyl-␣-l-iduronidase (50 m) (Sigma) in 0.4 m formate buffer (pH 4.5) for 15 min to 1 h duction, cells were maintained on the same irradiated stroma in long-term bone marrow culture (LTBMC) at room temperature. The amount of protein and the time of reaction used in each experiment were chosen to medium and re-fed twice weekly. Nonadherent cells were removed periodically for IDUA enzyme activity ensure that the enzymatic reaction occurred within a linear range. At the end of the incubation period, the reacassay.
tions were terminated by the addition of 1 ml of glycinecarbonate buffer (0.5 m, pH 10.2). Fluorescence of the libAnalysis of transduction efficiency To assess the gene transfer efficiency, the L-HuID-SN erated 4-methylumbelliferone (4-MU) was measured at 365 nm excitation and 440 nm emission using an F-2000 transduced hematopoietic cells were plated in semi-solid methylcellulose for progenitor c.f.u. assays with or withfluorescence spectrophotometer (Hitachi, Fremont, CA, USA). A standard curve of fluorescence emission of the out G418 (0.9 mg/ml). 25 Single colonies were also plucked using micropipette tips for PCR analysis from reaction product (4-MU) ranging from 0 to 1.0 nmol was performed in each experiment. A unit of IDUA enzyme both the L-HuID-SN-and the MFG-HuID-transduced hematopoietic cells plated in the semi-solid methylcelluactivity was defined as the release of 1 nmol of 4-MU per milligram of protein in 1 h reaction time at room temlose plates and not selected by G418. Samples containing 50-500 cells were soaked in 1 ml of PBS solution at room perature as described. 26 To measure the IDUA enzyme activity in cell medium, 25 l of culture medium was temperature for 1 h, cells were then pelleted and lysed in 20 l of whole cell lysis buffer (10 mm Tris-HCl, pH 8.3, used in each reaction instead of cell lysate and a unit of enzyme activity was defined as 1 nmol of 4-MU liberated 50 mm KCl, 1.5 mm MgCl 2 , 0.1 mg/ml gelatin, 0.45% Tween 20) with proteinase K (0.1 mg/ml) at 37°C for 2 h.
per millilter of cell medium in 1 h. Proteinase K was then inactivated at 94°C for 10 min and 2 l of cell lysate were used for each PCR amplification Enzyme uptake assay A confluent plate of Hurler fibroblasts (GM00415) was for the presence of vector-specific sequences. DNA from progeny of the L-HuID-SN transduced CD34
+ cells was trypsinized and the cells were plated at 2 × 10 5 cells per well in a six-well dish. Newly plated cells were allowed amplified to detect the presence of the neo gene of the to recover for 24 h before being used for enzyme uptake DK09430-02) and NIH grant number (DBK; R01 DK49000). assays. To measure the kinetic properties of IDUA produced by transduced human Hurler fibroblasts, culture medium-containing enzyme was harvested and concen-
